146 related articles for article (PubMed ID: 15448036)
21. [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].
de Mulder PH; Haanen JB; Sleijfer S; Kruit WH; Gietema JA; Richel DJ; Groenewegen G; Voest EE; van den Eertwegh AJ; Osanto S; Jansen RL; Mulders PF
Ned Tijdschr Geneeskd; 2008 Feb; 152(7):371-5. PubMed ID: 18380383
[TBL] [Abstract][Full Text] [Related]
22. New therapeutic options for renal cell carcinoma.
Stadler W
Clin Adv Hematol Oncol; 2006 Jun; 4(6):429-30. PubMed ID: 16981664
[No Abstract] [Full Text] [Related]
23. Toxicity of sorafenib: clinical and molecular aspects.
Blanchet B; Billemont B; Barete S; Garrigue H; Cabanes L; Coriat R; Francès C; Knebelmann B; Goldwasser F
Expert Opin Drug Saf; 2010 Mar; 9(2):275-87. PubMed ID: 20078249
[TBL] [Abstract][Full Text] [Related]
24. Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
Pouessel D; Culine S
Expert Rev Anticancer Ther; 2006 Dec; 6(12):1761-7. PubMed ID: 17181490
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib for the treatment of advanced renal cell carcinoma.
Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
[TBL] [Abstract][Full Text] [Related]
26. Treatment options for metastatic renal cell carcinoma: a review.
Athar U; Gentile TC
Can J Urol; 2008 Apr; 15(2):3954-66. PubMed ID: 18405442
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP
J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060
[TBL] [Abstract][Full Text] [Related]
28. Trials probe new agents for kidney cancer.
Hampton T
JAMA; 2006 Jul; 296(2):155-7. PubMed ID: 16835411
[No Abstract] [Full Text] [Related]
29. New therapies in renal cell carcinoma.
Patard JJ; Pouessel D; Culine S
Curr Opin Support Palliat Care; 2007 Oct; 1(3):174-9. PubMed ID: 18685359
[TBL] [Abstract][Full Text] [Related]
30. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Ratain MJ; Eisen T; Stadler WM; Flaherty KT; Kaye SB; Rosner GL; Gore M; Desai AA; Patnaik A; Xiong HQ; Rowinsky E; Abbruzzese JL; Xia C; Simantov R; Schwartz B; O'Dwyer PJ
J Clin Oncol; 2006 Jun; 24(16):2505-12. PubMed ID: 16636341
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.
Ryan CW; Goldman BH; Lara PN; Mack PC; Beer TM; Tangen CM; Lemmon D; Pan CX; Drabkin HA; Crawford ED;
J Clin Oncol; 2007 Aug; 25(22):3296-301. PubMed ID: 17664477
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
Grandinetti CA; Goldspiel BR
Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
[TBL] [Abstract][Full Text] [Related]
33. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
[TBL] [Abstract][Full Text] [Related]
34. Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell cacinoma guideline. Eur Urol 2007;51:1502-10.
Di Lorenzo G
Eur Urol; 2007 Sep; 52(3):926-8; author reply 928. PubMed ID: 17574728
[No Abstract] [Full Text] [Related]
35. [The role of angiogenesis in renal carcinoma].
Bussolati B; Satolli MA; Camussi G
G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
[TBL] [Abstract][Full Text] [Related]
36. Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma.
Gore ME; Escudier B
Oncology (Williston Park); 2006 May; 20(6 Suppl 5):19-24. PubMed ID: 16773841
[TBL] [Abstract][Full Text] [Related]
37. Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.
Hutson TE
Expert Rev Anticancer Ther; 2007 Sep; 7(9):1193-202. PubMed ID: 17892420
[TBL] [Abstract][Full Text] [Related]
38. Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.
Vira MA; Novakovic KR; Pinto PA; Linehan WM
BJU Int; 2007 May; 99(5 Pt B):1223-9. PubMed ID: 17441915
[No Abstract] [Full Text] [Related]
39. [Progress in therapeutic strategy for renal cell carcinoma].
Koga S; Kanetake H
Gan To Kagaku Ryoho; 2006 Feb; 33(2):171-7. PubMed ID: 16484851
[TBL] [Abstract][Full Text] [Related]
40. [Angiogenesis targeting in renal carcinomas].
Pouessel D; Culine S
Bull Cancer; 2007; 94(7 Suppl):F223-6. PubMed ID: 17965000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
